Florence Maude Thomas Cancer Research ProfessorDirector, Myeloma Section & Deputy Department ChairThe Department of Lymphoma & Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Dr. Robert Z. Orlowski holds the Florence Maude Thomas Cancer Research Professorship in the Department of Lymphoma/Myeloma, and also of Experimental Therapeutics, and serves as the Director of the Myeloma Section at The University of Texas MD Anderson Cancer Center. He completed his undergraduate education at Columbia University with a major in Chemistry, and obtained both an M.D. and a Ph.D., the latter in Molecular Biophysics and Biochemistry, at the Yale University School of Medicine and Yale University Graduate School, respectively. After completing an Internship and Residency at the Washington University in St. Louis’ Barnes Hospital in Medicine, he performed fellowships in Adult Hematology and Medical Oncology at the Johns Hopkins University School of Medicine and Johns Hopkins Oncology Center, respectively. Prior to arriving at MD Anderson, he was the Lenvel Lee Rothrock Associate Professor in Hematology/Oncology and Pharmacology at the University of North Carolina at Chapel Hill’s Lineberger Comprehensive Cancer Center.
Currently, Dr. Orlowski leads both laboratory- and clinically-based research programs with a particular focus on myeloma. In the laboratory arena, his focus is on identifying novel pathways and genes that contribute to myelomagenesis, validating novel therapies targeting these pathways, and understanding mechanisms of drug action and resistance. This research has been supported by multiple peer-reviewed research grants, and Dr. Orlowski currently serves as the Principal Investigator for the MD Anderson Cancer Center High Risk Multiple Myeloma Moon Shot, and the Leukemia & Lymphoma Society Specialized Center of Research in High Risk Plasma Cell Dyscrasias. In the clinical arena, Dr. Orlowski has been one of the leaders in translating novel laboratory findings into the clinic and in validating the efficacy of novel drugs and rationally designed combinations. Finally, he serves as the Chair of the SWOG Barlogie/Salmon Multiple Myeloma Committee as part of the National Clinical Trials Network.
Friday, September 29, 2023
2:15 PM – 4:15 PM EEST